कृपया अन्य खोज का प्रयास करें
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Patrick Couvreur | - | - | Member of Scientific Advisory Board |
Catherine Bréchignac | 75 | 2011 | Chairman of Scientific Advisory Board |
Peter J. Thornton | 57 | 2017 | Independent Director |
Linda S. Palczuk | 60 | 2018 | Independent Director |
Gregory J. Divis | 55 | 2017 | CEO & Director |
Jean-Marie Pierre Lehn | 83 | 2005 | Member of Scientific Advisory Board |
Christian Trepo | - | 2005 | Member of Scientific Advisory Board |
Geoffrey M. Glass | 48 | 2018 | Independent Non-Executive Chairman of the Board |
Mark A. McCamish | 69 | 2019 | Independent Director |
Eric J. Ende | 53 | 2018 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है